By Maureen Testoni Feb. 17, 2022– In many ways, last month’s 340B Coalition Winter Conference in San Diego was a cause for celebration. We celebrated the first chance we had to come together in person as a community in two years. And we celebrated the start of a historic year for the 340B drug pricing program, which will turn 30 years old this November. When 340B … [Read more...]
GlaxoSmithKline Policy Threatens Asthma Care
Feb. 16, 2022– Just days after President Biden spoke out in support of the 340B drug pricing program, drug giant GlaxoSmithKline (GSK) announced it will begin withholding 340B discounts starting in April for most safety-net hospitals. That action will bring the number of drug companies violating the 340B law to 14. In 2021, GSK reported more than $45 billion in global sales, … [Read more...]
Survey Shows the Loss of 340B Savings is a Big and Growing Problem for Safety-Net Hospitals
Feb. 2, 2022– More than a dozen pharmaceutical companies have pulled back on 340B drug pricing program discounts that federal law requires them to offer safety-net hospitals that care for the nation’s patients who are in the most need. New survey data demonstrate how these drugmaker actions already have taken major bites out of the resources that hospitals rely on to fulfill … [Read more...]
Housing is Health: 340B Helps Address Social Determinants of Health for Patients Living with HIV
Jan. 18, 2022 – When Ellen Eaton, M.D., reflects on how important the 340B drug pricing program is to her patients living with HIV, one of the first people she thinks about is a woman she calls “Linda.” For many years, Linda struggled with substance use disorders. She lost custody of her children, was estranged from her family, had no income, and she was living without stable … [Read more...]
More Court Battles Ahead for 340B in 2022
Jan. 12, 2022– The dispute between safety-net hospitals and a growing group of drug companies over community-based pharmacies in the 340B drug pricing program is heading into a new phase of legal wrangling that ensures this fight will remain a dominant issue in the 340B world for months to come. As 2021 ended, two industry giants – Amgen and AbbVie – joined the group of … [Read more...]
Recapping a Momentous Year for 340B
Dec. 31, 2021– Today is the final day of what might be one of the most eventful years in the history of the 340B drug pricing program. Key developments in the 340B world stood out even amid all the news about a global pandemic, a change in leadership in Washington, and an uneasy economic climate. As we wrap up 2021 and look forward to a new year, we are reflecting on some of … [Read more...]
A Hospital Community United Against Threats to 340B
Dec. 20, 2021— Hundreds of safety-net hospitals are urging the federal government to escalate its efforts to stop a group of drug companies that are refusing to offer drug discounts that the federal 340B drug pricing program requires. Today, more than 800 hospitals participating in 340B sent a letter to Health and Human Services (HHS) Secretary Xavier Becerra calling on the … [Read more...]